RxDoctor Payments Data

Joseph Paskowski, MD

Ophthalmology · Suffern, NYNPI 1144324179

Payments from drug & device makers

$3,904in general payments, 2019–2025

Across 163 payments — averaging $23.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$821
  • AbbVie$466
  • Sun Pharmaceutical Industries Inc.$329
  • Bausch & Lomb Americas Inc.$290
  • Coopervision Inc.$250
  • Novartis$201
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$3,904100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,904 in reported general payments places this provider in the 70th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$381,715
Medicare patients
1,264
Services billed
3,406

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine77$89,669
XiidraLifitegrast42$61,749
LumiganBimatoprost58$35,575
RocklatanNetarsudil Mesylat/Latanoprost18$16,257
Travoprost44$12,005
Bromfenac Sodium62$11,283
Cyclosporine17$11,280
RhopressaNetarsudil Mesylate14$10,273
Loteprednol Etabonate57$9,750
IlevroNepafenac24$8,828
CombiganBrimonidine Tartrate/Timolol21$8,303
Brimonidine Tartrate37$8,239
Prednisolone Acetate142$6,571
BesivanceBesifloxacin Hcl29$6,042
Latanoprost400$5,221

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$466$133,547156 claims
Bausch & Lomb Americas Inc.Xiidra$290$61,74942 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$121$26,53032 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Besivance$87$15,79286 claims
NovartisIlevro$201$8,82824 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in Suffern

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →